Search Result
Results for "
Pomalidomide 4'-alkylC4-acid
" in MedChemExpress (MCE) Product Catalog:
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-131886
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-alkylC4-acid (linker16) is a E3 Ligase Ligand-Linker Conjugate. Pomalidomide 4'-alkylC4-acid can be used for conjugation to a target protein ligand .
|
-
-
- HY-130737
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-alkylC5-acid (Example 3) is an E3 ligase ligand-linker conjugate containing a Pomalidomide (HY-10984) based cereblon (CRBN) ligand and a linker. Pomalidomide 4'-alkylC5-acid can be used in the synthesis of PROTAC .
|
-
-
- HY-139333
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-PEG5-azide is the Pomalidomide (HY-123324)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide 4'-PEG5-azide can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-139339
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-alkylC6-azide is the Pomalidomide (HY-123324)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide 4'-alkylC6-azide can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-155560
-
Pomalidomide 4'-alkylC7-amine
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C7-NH2 (Pomalidomide 4'-alkylC7-amine) (Compound 24g) is an E3 Ligase Ligand-Linker Conjugates consisting of Pomalidomide (HY-10984) and a linker. Pomalidomide-C7-NH2 can be used for synthesis of PROTACs .
|
-
-
- HY-131875
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-alkylC3-acid is the E3 ligase ligand-linker conjugate used in the recruitment of CRBN protein. Pomalidomide 4'-alkylC3-acid can be used to synthesize PROTACs .
|
-
-
- HY-139343
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-alkylC2-azide (compound 2a) is an E3 ligase ligand-linker conjugate containing a Pomalidomide (HY-10984) based cereblon (CRBN) ligand and a linker. Pomalidomide 4'-alkylC2-azide can be used in the synthesis of PROTAC .
|
-
-
- HY-139341
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-alkylC3-azide (compound 2a) is an E3 ligase ligand-linker conjugate containing a Pomalidomide (HY-10984) based cereblon (CRBN) ligand and a linker. Pomalidomide 4'-alkylC3-azide can be used in the synthesis of PROTAC .
|
-
-
- HY-139332
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-PEG6-azide (compound 33e) is the E3 ligase ligand-linker conjugate used in the recruitment of CRBN protein. Pomalidomide 4'-alkylC3-acid can be used to synthesize PROTACs .
|
-
-
- HY-131863
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-alkylC8-acid is an E3 ubiquitin ligase ligand-Linker conjugate containing Pomalidomide (HY-10984). Pomalidomide is a third-generation immunomodulator that acts like a molecular glue. Pomalidomide interacts with the E3 ligase cereblon to induce degradation of the essential Ikaros transcription factor .
|
-
-
- HY-131872
-
Pomalidomide 4'-PEG2-acid
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG2-COOH (Pomalidomide 4'-PEG2-acid) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology .
|
-
-
- HY-130652
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and a linker. Pomalidomide 4'-PEG3-azide can be used for the synthesis of iRucaparib-TP3 (Compound 3). iRucaparib-TP3 is a highly efficient PARP1?degrader based on Rucaparib by using the PROTAC approach . Pomalidomide 4'-PEG3-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
-
- HY-132208
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-PEG2-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology . Pomalidomide 4'-PEG2-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
-
- HY-131878
-
Pomalidomide 4'-alkylC7-amine hydrochloride
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C7-NH2 (Pomalidomide 4'-alkylC7-amine) hydrochloride is an E3 ligase ligand-linker conjugate. Pomalidomide-C7-NH2 hydrochloride can be used for the synthesis of PROTAC .
|
-
-
- HY-131647
-
Pomalidomide-PEG5-CO2H
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 4'-PEG5-acid (Pomalidomide-PEG5-CO2H) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 5-unit PEG linker used in PROTAC technology .
|
-
-
- HY-123324
-
5-Hydroxy Pomalidomide; CC-17368
|
Ligands for E3 Ligase
|
Cancer
|
Pomalidomide-5-OH (5-hydroxy pomalidomide) is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-OH can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-139540
-
|
Ligands for E3 Ligase
|
Cancer
|
Pomalidomide-6-OH is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-6-OH can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-160017
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5'-C8-acid (Compound 3d') is an E3 ligase ligand-linker conjugate containing a Pomalidomide (HY-10984) based cereblon (CRBN) ligand and a linker. Pomalidomide-5'-C8-acid can be used in the synthesis of PROTACs .
|
-
-
- HY-169232
-
|
PROTACs
|
Cancer
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
-
- HY-139541
-
|
Ligands for E3 Ligase
|
Cancer
|
Pomalidomide-5-O-CH3 is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-O-CH3 can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-139542
-
|
Ligands for E3 Ligase
|
Cancer
|
Pomalidomide-6-O-CH3 is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-6-O-CH3 can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-137905
-
|
Others
|
Cancer
|
Pomalidomide-amido-C5-PEG2-C6-chlorine is a derivant of Pomalidomide (HY-10984) .
|
-
-
- HY-155259
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C3-NH2 hydrochloride is the Pomalidomide (HY-10984)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-C3-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-155260
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C4-NH2 hydrochloride is the Pomalidomide (HY-10984)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-C4-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-155261
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C5-NH2 hydrochloride is the Pomalidomide (HY-10984)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-C5-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-155262
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C6-NH2 hydrochloride is the Pomalidomide (HY-10984)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-C6-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-155264
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C8-NH2 hydrochloride is the Pomalidomide (HY-10984)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-C8-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-10984S2
-
-
-
- HY-133699
-
|
E3 Ligase Ligand-Linker Conjugates
|
Others
|
Pomalidomide-PEG4-COOH is a E3 ligase ligand-linker conjugate. Pomalidomide-PEG4-COOH contains the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology (extracted from patent WO2017184995A1) .
|
-
-
- HY-130617
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amido-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (HY-111758). PROTAC B-Raf degrader 1 has anti-cancer activity .
|
-
-
- HY-148362
-
-
-
- HY-139996
-
|
PROTACs
Apoptosis
FLT3
c-Kit
FGFR
VEGFR
PDGFR
c-Fms
|
Cancer
|
Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells. Pomalidomide-C5-Dovitinib induces the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely blocks their downstream signaling pathway. Pomalidomide-C5-Dovitinib has the potential for the research of FLT3-ITD + acute myeloid leukemia .
|
-
-
- HY-163210
-
|
Ligands for E3 Ligase
|
Cancer
|
Pomalidomide 5'-fluoro-6'-piperazine-4-methylpiperidine hydrochloride (ZJT1) is an E3 ubiquitin ligase cereblon based on Pomalidomide (HY-10984) (CRBN) ligand for recruitment of cereblon protein. Pomalidomide 5'-fluoro-6'-piperazine-4-methylpiperidine hydrochloride can be linked to protein ligand by linker to form PROTAC .
|
-
-
- HY-128716A
-
Cereblon Ligand-Linker Conjugates 5 TFA; E3 ligase Ligand-Linker Conjugates 30 TFA
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 5 (TFA)) is a synthetic E3 ligase ligand-linker conjugate comprising a Pomalidomide (HY-10984)-based cereblon ligand and a 3-unit PEG linker. Pomalidomide-PEG3-C2-NH2 TFA can be used for the synthesis of PROTACs .
|
-
-
- HY-10984R
-
|
Ligands for E3 Ligase
Molecular Glues
Apoptosis
|
Cancer
|
Pomalidomide (Standard) is the analytical standard of Pomalidomide. This product is intended for research and analytical applications. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
|
-
-
- HY-131887
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C6-COOH is the pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-6-OH can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-123215
-
7-Hydroxy Pomalidomide; Pomalidomide metabolite M16
|
Ligands for E3 Ligase
|
Cancer
|
CC-17369 (7-Hydroxy pomalidomide) is a metabolite of Pomalidomide. CC-17369 is the Pomalidomide -based cereblon (CRBN) ligand used in the recruitment of CRBN protein. CC-17369 can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-10984
-
Pomalidomide
Maximum Cited Publications
16 Publications Verification
CC-4047
|
Ligands for E3 Ligase
Molecular Glues
Apoptosis
|
Cancer
|
Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
|
-
-
- HY-155263
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C7-NH2 hydrochloride is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-C7-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-155270
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C14-NH2 hydrochloride is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-C14-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
-
- HY-150006
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C2-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
-
- HY-159165
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-cyclopentane-amide-Alkyne is an E3 ligase ligand-linker conjugate that incorporates the Pomalidomide (HY-10984) and the linker cyclopentane-amide-Alkyne. Pomalidomide-cyclopentane-amide-Alkyne is used to form PROTACs, such as RGB110 (HY-159087) .
|
-
-
- HY-163928
-
-
-
- HY-155269
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C13-NH2 hydrochloride is a Pomalidomide (HY-10984)-based E3 ubiquitin ligase cereblon (CRBN) ligand for recruiting cereblon proteins. Pomalidomide-5-C13-NH2 hydrochloride can be connected to protein ligands through a linker to form PROTAC.
|
-
-
- HY-148142
-
-
-
- HY-148143
-
-
-
- HY-W998262
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide 5-piperidylamine is the conjugate of an E3 ligase ligand and a linker. Pomalidomide 5-piperidylamine can be used for synthesis of PROTAC PARP1 degrader-2 (HY-164306) .
|
-
-
- HY-10984S
-
-
-
- HY-W580022
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5'-PEG8-C2-COOH is an E3 Ligase Ligand-Linker Conjugates, consisting of Pomalidomide (HY-10984) and a linker. Pomalidomide-5'-PEG8-C2-COOH can be used for synthesis of PROTACs .
|
-
-
- HY-155266
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C10-NH2 hydrochloride is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.Pomalidomide-5-C10-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
- HY-155267
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C11-NH2 hydrochloride is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.Pomalidomide-5-C11-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
- HY-155268
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C12-NH2 hydrochloride is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.Pomalidomide-5-C12-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
- HY-155265
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-5-C9-NH2 hydrochloride is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.Pomalidomide-5-C9-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
- HY-153337
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C11-NH2 is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-C11-NH2 can be connected to the ligand for protein by a linker to form PROTAC .
|
-
- HY-153337A
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C11-NH2 hydrochloride is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.Pomalidomide-C11-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
- HY-155258
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG7-NH2 hydrochloride is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.Pomalidomide-PEG7-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
- HY-10984S1
-
CC-4047-d3
|
Ligands for E3 Ligase
Molecular Glues
Apoptosis
|
Cancer
|
Pomalidomide-d3 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors[1][2].
|
-
- HY-148834
-
-
- HY-148484
-
|
Others
|
Others
|
Pomalidomide-5'-PEG5-C2-COOH is an active compound. Pomalidomide-5'-PEG5-C2-COOH can be used for the research of various biochemical .
|
-
- HY-160244
-
|
Ligands for E3 Ligase
|
Cancer
|
Pomalidomide 5'-piperazine-4-methylpiperidine dihydrochloride is the Pomalidomide (HY-10984)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide 5'-piperazine-4-methylpiperidine dihydrochloride can be connected to the ligand for protein by a linker to form PROTAC.
|
-
- HY-10984A
-
(S)-CC-4047
|
Others
|
Cancer
|
(S)-Pomalidomide ((S)-CC-4047) is an angiogenesis-inhibiting drug with growth-inhibitory activity against B-cell tumors. (S)-Pomalidomide can induce complete tumor regression in BurKitt lymphoma cells. (S)-Pomalidomide serves as an immunomodulator with potential applications in inhibiting hematological malignancies .
|
-
- HY-133138
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker.?Pomalidomide-PEG1-azide?can be used to design a?PROTAC BRD4 Degrader-1 (HY-133131) . Pomalidomide-PEG1-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-133799
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C7-COOH is a synthesized E3 ligase cereblon ligand-linker conjugate. Pomalidomide-C7-COOH is an intermediate for the synthesis of PROTAC BCL-XL degraders .
|
-
- HY-170350
-
-
- HY-131185
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.
|
-
- HY-W924949
-
|
E3 Ligase Ligand-Linker Conjugates
|
Others
|
Pomalidomide-PEG3-OH (compound 53a) is an E3 Ligase Ligand-Linker Conjugates consisting of a pomalidomide (HY-10984)-based cereblon ligand and a 2-unit PEG linker .
|
-
- HY-W924948
-
|
E3 Ligase Ligand-Linker Conjugates
|
Others
|
Pomalidomide-PEG3-OH (compound 53b) is an E3 Ligase Ligand-Linker Conjugates consisting of a pomalidomide (HY-10984)-based cereblon ligand and a 3-unit PEG linker .
|
-
- HY-132944
-
|
Ligands for E3 Ligase
|
Cancer
|
(R)-Pomalidomide-pyrrolidine, a CRBN ligand, can be connected to the ligand for protein by a linker to form PROTACs.
|
-
- HY-138845
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-131888A
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-131888
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-138845A
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-133618
-
|
Wee1
PROTACs
|
Cancer
|
Pomalidomide-C3-adavosertib is a rapid and selective PROTAC Wee1 degrader (IC50=3.58 nM). Pomalidomide-C3-adavosertib shows anti-cancer cell proliferation activity, and induces apoptosis .
|
-
- HY-136156
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG6-butyl iodide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology .
|
-
- HY-136161
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.
|
-
- HY-138965A
-
-
- HY-141015
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG4-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology . Pomalidomide-PEG4-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-169010
-
|
E3 Ligase Ligand-Linker Conjugates
|
Infection
|
Pomalidomide-CO-C5-Br (Compound 6b) is a conjugated compound of the E3 ligand Pomalidomide and linker. It can be used to synthesize highly effective PROTAC molecules targeting ADC (HY-169008) .
|
-
- HY-W957364
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C2-Br is an E3 Ligase Ligand (HY-14658) and linker (HY-W007731) conjugate. Pomalidomide-C2-Br can be used to synthesize PROTAC AR Degrader-8 (HY-170329) .
|
-
- HY-136772
-
|
E3 Ligase Ligand-Linker Conjugates
|
Others
|
Pomalidomide-PEG1-NH2 hydrochloride is a crosslinker-E3 ligase ligand conjugate, consisting of an E3 ligase ligand pomalidomide and a PEGylated crosslinker with terminal amine for reactivity with a carboxyl group on the target ligand .
|
-
- HY-160077
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-CO-C5-azide (Compound PA) is a ligand for E3 ligase bearing a bioorthogonal group azide. Pomalidomide-CO-C5-azide can be used to synthesize PROTACs with anticancer activity .
|
-
- HY-138859
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amino-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-138859A
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amino-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-133817A
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amino-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-133817
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amino-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-133816A
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amino-PEG5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-133816
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amino-PEG5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-137537
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG2-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology . Pomalidomide-PEG2-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-137538
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology . Pomalidomide-PEG3-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-148662
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG5-C2-NH2 hydrochloride is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein.Pomalidomide-PEG5-C2-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC .
|
-
- HY-160235
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C2-amide-C5-azidea is an E3 linker conjugate, pomalidomide, that can be used to synthesize highly effective PROTAC molecules towards CDK9. Pomalidomide-C2-amide-C5-azidea has antiproliferative activity .
|
-
- HY-168544
-
-
- HY-168541
-
-
- HY-164391
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C2-amide-C4-Br is an E3 ligase ligand-linker conjugate containing a Pomalidomide (HY-10984) based cereblon (CRBN) ligand and a linker. Pomalidomide-C2-amide-C4-Br can be used in the synthesis of PROTACs .
|
-
- HY-137531
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG1-C2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology .
|
-
- HY-156726
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amino-PEG4-C4-Cl (Intermediate 4d) is an E3 ligase ligand-linker conjugate containing a Pomalidomide (HY-10984) based cereblon (CRBN) ligand and a linker. Pomalidomide-amino-PEG4-C4-Cl can be used in the synthesis of PROTAC .
|
-
- HY-163986
-
-
- HY-112599B
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in the synthesis of PROTACs..
|
-
- HY-130295
-
-
- HY-158383
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-CO-C3-PEG4-C6-NH2 is an E3 ligase ligand-linker conjugate part of PROTAC PIPIB degrader 1 (HY-158381). Pomalidomide consists of the E3 ligase ligand Pomalidomide (HY-10984) and a linker .
|
-
- HY-139336
-
-
- HY-131186
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amido-C3-piperazine-N-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183) .
|
-
- HY-128846A
-
Cereblon Ligand-Linker Conjugates 15 hydrochloride
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.
|
-
- HY-128846
-
Cereblon Ligand-Linker Conjugates 15
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology.
|
-
- HY-10984S3
-
-
- HY-163678
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-CO-C7-NH-CO-C3-COOH is a conjugate of a ligand for E3 ligase and a linker. Pomalidomide-CO-C7-NH-CO-C3-COOH can be used for synthesis of PROTAC degrader ARM165 (HY-163677) .
|
-
- HY-161250
-
|
PROTACs
|
Cancer
|
Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader, which contains a CRBN ligands Pomalidomide, a 24-atom linker with 6 PEG units and a HAT inhibitor CPI-1612. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 exhibits antiproliferative effects in cells multiple myeloma cells LP1 (with a DC50 of 1.2 μM), MM1S and various cancer cell lines, especially the leukemia cells .
|
-
- HY-145615
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C12-NH2 hydrochloride is the E3 ligase ligand-linker conjugate of PROTAC KRAS G12C degrader-1 (HY-139186). PROTAC KRAS G12C degrader-1 is a Cereblon-based KRAS G12C degrader .
|
-
- HY-169237
-
-
- HY-130835
-
RC32
|
PROTACs
FKBP
|
Cancer
|
FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an Cereblon E3 ubiquitin ligase (Pomalidomide; HY-10984) .
|
-
- HY-21930
-
Cereblon Ligand -Linker Conjugates 1; E3 Ligase Ligand-Linker Conjugates 1
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG4-C-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
|
-
- HY-41549
-
Cereblon Ligand-Linker Conjugates 9; E3 Ligase Ligand-Linker Conjugates 2
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG4-Ph-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
|
-
- HY-112599
-
Cereblon Ligand-Linker Conjugates 8; E3 Ligase Ligand-Linker Conjugates 22
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
|
-
- HY-128716
-
Cereblon Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 30
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.
|
-
- HY-125884
-
Cereblon Ligand-Linker Conjugates 21; E3 Ligase Ligand-Linker Conjugates 54
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amido-C4-amido-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.
|
-
- HY-128716B
-
Cereblon Ligand-Linker Conjugates 5 hydrochloride; E3 ligase Ligand-Linker Conjugates 30 hydrochloride
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 5) hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology .
|
-
- HY-130521
-
Cereblon Ligand-Linker Conjugates 22; E3 ligase Ligand-Linker Conjugates 55
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 22) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology .
|
-
- HY-125883
-
Cereblon Ligand-Linker Conjugates 20; E3 Ligase Ligand-Linker Conjugates 53
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.
|
-
- HY-125843
-
Cereblon Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 50
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-PEG1-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology. Pomalidomide-PEG1-C2-N3 can be used to design a selective CDK6 PROTAC degrader CP-10. CP-10 induces the degradation of CDK6 with an DC50 of 2.1 nM . Pomalidomide-PEG1-C2-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-128848
-
Cereblon Ligand-Linker Conjugates 14; E3 ligase Ligand-Linker Conjugates 49
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.
|
-
- HY-163238
-
|
Ligands for E3 Ligase
Autophagy
|
Cancer
|
Thalidomide-azetidine-CH-piperazineethanol is a conjugate of E3 ligase ligand and linker, consisting of Thalidomide (HY-14658) and the corresponding Linker. Thalidomide-azetidine-CH-piperazineethanol can serve as a Cereblon ligand to recruit CRBN protein and serve as a key intermediate for the synthesis of complete PROTAC molecules.
|
-
- HY-163236
-
|
Ligands for E3 Ligase
Autophagy
|
Cancer
|
Thalidomide-piperidine-O-azetidine-acetic acid is a conjugate of E3 ligase ligand and linker, consisting of Thalidomide (HY-14658) and the corresponding Linker. Thalidomide-piperidine-O-azetidine-acetic acid can serve as a Cereblon ligand to recruit CRBN protein and serve as a key intermediate for the synthesis of complete PROTAC molecules.
|
-
- HY-163239
-
|
Ligands for E3 Ligase
Autophagy
|
Cancer
|
(R)-Thalidomide-piperazine-pyrrolidineethanol is a conjugate of E3 ligase ligand and linker, consisting of Thalidomide (HY-14658) and the corresponding Linker. (R)-Thalidomide-piperazine-pyrrolidineethanol can serve as Cereblon ligand to recruit CRBN protein and serve as a key intermediate for the synthesis of complete PROTAC molecules.
|
-
- HY-137340
-
|
PROTACs
|
Cancer
|
WH-10417-099 is a CRBN-type PROTAC multi-kinase degrader that can jointly induce the degradation of the largest number of unique kinases (more than 125 unique kinases). WH-10417-099 induces protein degradation through the ubiquitin biotinylation (E-STUB) pathway and consists of the target protein ligand (red part) PI3Kγ ligand 1 (HY-168319), the E3 ubiquitin ligase ligand (blue part) Thalidomide 4-fluoride (HY-41547) and the PROTAC linker (black part) Amino-PEG5-C2-acid (HY-115384). The E3 ligase ligand and linker can form a conjugate Pomalidomide 4'-PEG5-acid (HY-131647).
|
-
- HY-117884
-
|
Apoptosis
|
Cancer
|
(Rac)-CCT 250863 (compound rac-21) is a selective and reversible NEK 2 inhibitor with an IC50 of 0.073 µM. (Rac)-CCT 250863 shows good effects of inducing cell cycle arrest and also can antiproliferative in cells (Pomalidomide sensitive/resistant). (Rac)-CCT 250863 induces apoptosis when combines with Pomalidomide .
|
-
- HY-162875
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC BRD4 Degrader-27 (compound 6b) is a PROTAC that selectively targets BRD4 (rather than BRD2/BRD3) and can also inhibit the expression of KLF5 transcription factor and exert anti-cancer activity. PROTAC BRD4 Degrader-27 is composed of E3 ubiquitinase ligand Thalidomide-4-OH (HY-103596) (red part), PROTAC Linker γ-Aminobutyric acid (HY-N0067) (black part) and PROTAC target protein ligand PROTAC BRD4 ligand-3 (HY-162876) (blue part), of which the active control of the target protein ligand is Mivebresib (HY-100015), and the conjugate of E3 ubiquitin ligase ligand + Linker is Pomalidomide 4'-alkylC3-acid (HY-131875) [1] .
|
-
- HY-157215
-
|
HDAC
|
Cancer
|
HDAC-IN-66 (compound 2F) is a selective HDAC inhibitor and Pomalidomide (HY-10984) derivative that potently inhibits hematological tumor cells .
|
-
- HY-161452
-
-
- HY-139344
-
|
FAK
PROTACs
|
Cancer
|
FC-11 is a PROTAC FAK degrader (DC90: 1 nM) . FC-11 contains CRBN ligand Pomalidomide (HY-10984), linker and FAK ligand PF562271 (HY-10459) .
|
-
- HY-161209
-
|
Ligands for E3 Ligase
Autophagy
|
Cancer
|
Thalidomide-2,6-diazaspiro[3.4]octane-C-Pip-boc is a conjugate of E3 ligase ligand and linker, consisting of Thalidomide (HY-14658) and the corresponding Linker. Thalidomide-2,6-diazaspiro[3.4]octane-C-Pip-boc can serve as a Cereblon ligand to recruit CRBN protein and serve as a key intermediate for the synthesis of complete PROTAC molecules.
|
-
- HY-163225
-
|
Ligands for E3 Ligase
Autophagy
|
Cancer
|
(S)-Thalidomide-piperazine-(1S,4r)-cyclohexane-NH-Boc is a conjugate of E3 ligase ligand and linker, consisting of Thalidomide (HY-14658) and the corresponding Linker. (S)-Thalidomide-piperazine-(1S,4r)-cyclohexane-NH-Boc can serve as a Cereblon ligand to recruit CRBN protein and serve as a key intermediate for the synthesis of complete PROTAC molecules.
|
-
- HY-W797383
-
-
- HY-P10218A
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P10218
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-133702
-
|
PROTAC Linkers
|
Cancer
|
Aniline-piperazine-C3-NH-Boc (Compound Int-3) is a PROTAC linker, and can be used for synthesis of Pomalidomide-C3-adavosertib (HY-133618) and AZD1775 (HY-10993) (a Wee1 inhibitor) .
|
-
- HY-P10876
-
|
Amyloid-β
|
Neurological Disease
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
- HY-P99536
-
SL-401
|
Interleukin Related
|
Cancer
|
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
|
-
- HY-148275
-
|
PROTACs
IRAK
|
Cancer
|
KTX-955 is an antumor and effective IRAK4 degrader, with DC50 values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively . KTX-955 is composed of CRBN ligand (blue part) Pomalidomide (HY-10984) and target protein ligand (red part) IRAK4-IN-20 (HY-150735).
|
-
- HY-P10318
-
|
GLP Receptor
|
Endocrinology
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
- HY-110167
-
|
PGE synthase
Ligands for Target Protein for PROTAC
|
Cancer
|
TFC-007, a selective hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, show high inhibitory activity against H-PGDS enzyme (IC50 value of 83 nM). TFC-007 can be used for composing H-PGDS degradation inducer PROTAC(H-PGDS)-1 (TFC-007 binds to H-PGDS, and Pomalidomide binds to cereblon) .
|
-
- HY-151902
-
|
PROTACs
JAK
|
Cancer
|
SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL) .
|
-
- HY-P10200
-
|
Bacterial
|
Infection
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
-
- HY-169481
-
|
PROTACs
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
AP-1 is a PROTAC targeting anaplastic lymphoma kinase (ALK). AP-1 is composed of PROTAC target protein ligand CS-1243648 (HY-169482) (red part), E3 ligase ligand Pomalidomide (HY-10984) (blue part) and PROTAC Linker 2-(Tert-Butoxy)-2-oxoacetic acid (HY-W687662) (black part) .
|
-
- HY-P0041
-
-
- HY-P0041A
-
-
- HY-P3462
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P5161A
-
-
- HY-P5161
-
-
- HY-111546
-
BI-3663
1 Publications Verification
|
PROTACs
FAK
|
Cancer
|
BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker . Anti-cancer activity .
|
-
- HY-123919
-
|
PROTACs
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC50 value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC50 values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib?(HY-15656) and the Cereblon ligand of Pomalidomide (HY-10984) .
|
-
- HY-148290
-
|
PROTACs
IRAK
|
Cancer
|
KTX-951 is an orally active IRAK4 and IMiD (Ikaros/Aiolos) substrates PROTAC degrader. KTX-951 has DC50 of 13 nM, 14 nM and 13 nM for IRAK4, Ikaros and Aiolos, respectively. TX-951 has antitumor activity.(Pink: IRAK4 ligand-12 (HY-48932); Black: Linker (HY-W382009); Blue: CRBN Ligand Pomalidomide (HY-10984))
|
-
- HY-P10271
-
|
GLP Receptor
|
Metabolic Disease
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
- HY-122582
-
|
PROTACs
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
TL13-12 is a potent and selective?ALK-PROTAC?degrader and inhibits?ALK?activity with an IC50 value of 0.69 nM. TL13-12 also prompts the degradation of additional kinases including Aurora A, FER, PTK2, and RPS6KA1 with IC50 values of 13.5 nM, 5.74 nM, 18.4 nM, and 65 nM, respectively. TL13-12 is comprised of the conjugation of TAE684 (HY-10192) and the Cereblon ligand of Pomalidomide (HY-10984) .
|
-
- HY-161668
-
|
Ligands for E3 Ligase
Ferroptosis
|
Cancer
|
Ru-Poma is a Ru(II)-based photosensitizer, which attenuates Cisplatin (HY-17394)-resistant tumor through photodynamic therapy (PDT). Ru-Poma photodegrades CRBN through a Pomalidomide (HY-10984) moiety. Ru-Poma induces ferroptosis, through an increase in lipid peroxide, downregulation of GPX4 and GAPDH expression. Ru-Poma exhibits cytotoxicity in A549, with IC50 of 18.46 μM and 0.37 μM in dark and upon irradiation, respectively .
|
-
- HY-163677
-
|
PROTACs
PI3K
Akt
|
Cancer
|
ARM165 is a heterobifunctional molecule. ARM165 degrades the PIK3CG proteins, inhibits PI3Kγ-Akt signaling pathway, and thus exhibits antileukemia efficacy. ARM165 inhibits proliferations of AML cells, with IC50 <1 μM. (Pink: ligand for target protein PI3Kγ inhibitor AZ2 (HY-111570); Black: linker; Blue: ligand for E3 ligase Pomalidomide (HY-10984))
|
-
- HY-P10341
-
|
GCGR
|
Metabolic Disease
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
- HY-P3143
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50?of 7.68?nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST?and SPR assays, respectively.?BMSpep-57?facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P3143A
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-134850
-
|
PROTACs
Tau Protein
|
Neurological Disease
|
QC-01-175 is a heterobifunctional molecule, which degrades aberrant tau. QC-01-175 reduces the levels of A152T and P301L mutant tau protein and protects neurons from tau-mediated toxicity and improve cell survival (Pink: ligand for target protein Aberrant tau ligand 1 (HY-W453397); Black: linker NH2-PEG3 (HY-W007545); Blue: ligand for E3 ligase Pomalidomide (HY-10984)) .
|
-
- HY-125876
-
|
PROTACs
Bcl-2 Family
|
Cancer
|
PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which potently and selectively induces the degradation of Bcl-2 (IC50, 4.94 μM; DC50, 3.0 μM) and Mcl-1 (IC50, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1 (Blue: CRBN ligand, Black: linker;Pink: Mcl-1/Bcl-2 inhibitor, Nap-1).
|
-
- HY-162723
-
|
PROTACs
AP-1
|
Cancer
|
FOSL1 degrader 1 (4) is a T-5224-PROTAC, potently degrade FOSL1 (AP-1) to suppress cancer stemness gene expression in HNSCC. FOSL1 degrader 1 (4) effectively eliminate HNSCC cancer stem cells to inhibit tumor growth through degrading FOSL1. FOSL1 degrader 1 (4) displays around 30- to 100-fold increased potency over T-5224 (Pink: T-5224 (HY-12270); Black: Linker (HY-130200); Blue: Pomalidomide (HY-10984)) .
|
-
- HY-113560
-
-
- HY-P4146
-
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P4146A
-
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P1162
-
-
- HY-P10031
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
- HY-P10031A
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors. SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
- HY-P10272
-
PTG-300
|
Ferroportin
|
Others
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
- HY-P4895
-
|
Oxytocin Receptor
|
Neurological Disease
|
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
|
-
- HY-168131
-
|
PROTACs
Histone Methyltransferase
Apoptosis
|
Cancer
|
PROTAC EZH2 Degrader-3 (compound ZJ-20) is a EZH2 PROTAC degrader. PROTAC EZH2 Degrader-3 (5 μM, 24 h) not only potently inhibits the expression of EZH2 protein, but also had a strong inhibits effect on the expression levels of other subunits of PRC2 as well as H3k27me3 protein. PROTAC EZH2 Degrader-3 shows anti-proliferative activity and blocks the cell cycle in the G0-G1 phase and induces cell apoptosis((Blue: cereblon ligand Pomalidomide (HY-10984), Black: linker HY-W361751;Pink: EZH2 inhibitor Tazemetostat (HY-13803)) .
|
-
- HY-P10563
-
BHV-1100
|
CD38
|
Cancer
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10218A
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P0041A
-
-
- HY-P3462
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-169232
-
|
PROTACs
|
Cancer
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
- HY-P10218
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P10876
-
|
Amyloid-β
|
Neurological Disease
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
- HY-P10318
-
|
GLP Receptor
|
Endocrinology
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
- HY-P4837
-
|
Peptides
|
Others
|
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P10200
-
|
Bacterial
|
Infection
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
-
- HY-P0041
-
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P5161A
-
-
- HY-P5161
-
-
- HY-P10271
-
|
GLP Receptor
|
Metabolic Disease
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
- HY-P10341
-
|
GCGR
|
Metabolic Disease
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
- HY-P3143
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50?of 7.68?nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST?and SPR assays, respectively.?BMSpep-57?facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P3143A
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-113560
-
-
- HY-P10381
-
|
Peptides
|
Others
|
palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC50: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .
|
-
- HY-P4146
-
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P4146A
-
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P1162
-
-
- HY-P2595
-
|
Peptides
|
Cardiovascular Disease
|
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
|
-
- HY-P10031
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
- HY-P10031A
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors. SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
- HY-P10272
-
PTG-300
|
Ferroportin
|
Others
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
- HY-P4895
-
|
Oxytocin Receptor
|
Neurological Disease
|
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
|
-
- HY-P10563
-
BHV-1100
|
CD38
|
Cancer
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99536
-
SL-401
|
Interleukin Related
|
Cancer
|
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
|
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-10984S2
-
|
Pomalidomide-d4 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<
|
-
-
- HY-10984S1
-
|
Pomalidomide-d3 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors[1][2].
|
-
-
- HY-10984S
-
|
Pomalidomide-d5 is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
|
-
-
- HY-10984S3
-
|
Pomalidomide- 15N, 13C5 is 15N and 13C labeled Pomalidomide (HY-10984). Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-130652
-
|
|
Azide
|
Pomalidomide 4'-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and a linker. Pomalidomide 4'-PEG3-azide can be used for the synthesis of iRucaparib-TP3 (Compound 3). iRucaparib-TP3 is a highly efficient PARP1?degrader based on Rucaparib by using the PROTAC approach . Pomalidomide 4'-PEG3-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-132208
-
|
|
Azide
|
Pomalidomide 4'-PEG2-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology . Pomalidomide 4'-PEG2-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-133138
-
|
|
Azide
|
Pomalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker.?Pomalidomide-PEG1-azide?can be used to design a?PROTAC BRD4 Degrader-1 (HY-133131) . Pomalidomide-PEG1-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-139333
-
|
|
Azide
|
Pomalidomide 4'-PEG5-azide is the Pomalidomide (HY-123324)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide 4'-PEG5-azide can be connected to the ligand for protein by a linker to form PROTAC .
|
-
- HY-139339
-
|
|
Azide
|
Pomalidomide 4'-alkylC6-azide is the Pomalidomide (HY-123324)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide 4'-alkylC6-azide can be connected to the ligand for protein by a linker to form PROTAC .
|
-
- HY-139343
-
|
|
Azide
|
Pomalidomide 4'-alkylC2-azide (compound 2a) is an E3 ligase ligand-linker conjugate containing a Pomalidomide (HY-10984) based cereblon (CRBN) ligand and a linker. Pomalidomide 4'-alkylC2-azide can be used in the synthesis of PROTAC .
|
-
- HY-139341
-
|
|
Azide
|
Pomalidomide 4'-alkylC3-azide (compound 2a) is an E3 ligase ligand-linker conjugate containing a Pomalidomide (HY-10984) based cereblon (CRBN) ligand and a linker. Pomalidomide 4'-alkylC3-azide can be used in the synthesis of PROTAC .
|
-
- HY-139332
-
|
|
Azide
|
Pomalidomide 4'-PEG6-azide (compound 33e) is the E3 ligase ligand-linker conjugate used in the recruitment of CRBN protein. Pomalidomide 4'-alkylC3-acid can be used to synthesize PROTACs .
|
-
- HY-W457949
-
|
|
Azide
|
Pomalidomide 4'-alkylC4-azide (Compound 2) is an azide compound containing a MIDI group and is one of the compounds used to construct a library of MIDI azide compounds. Pomalidomide 4'-alkylC4-azide can be used to develop research on PROTAC degraders .
|
-
- HY-159165
-
|
|
Alkynes
|
Pomalidomide-cyclopentane-amide-Alkyne is an E3 ligase ligand-linker conjugate that incorporates the Pomalidomide (HY-10984) and the linker cyclopentane-amide-Alkyne. Pomalidomide-cyclopentane-amide-Alkyne is used to form PROTACs, such as RGB110 (HY-159087) .
|
-
- HY-141015
-
|
|
Azide
|
Pomalidomide-PEG4-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology . Pomalidomide-PEG4-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-160077
-
|
|
Azide
|
Pomalidomide-CO-C5-azide (Compound PA) is a ligand for E3 ligase bearing a bioorthogonal group azide. Pomalidomide-CO-C5-azide can be used to synthesize PROTACs with anticancer activity .
|
-
- HY-137537
-
|
|
Azide
|
Pomalidomide-PEG2-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology . Pomalidomide-PEG2-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-137538
-
|
|
Azide
|
Pomalidomide-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology . Pomalidomide-PEG3-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-125843
-
Cereblon Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 50
|
|
Azide
|
Pomalidomide-PEG1-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology. Pomalidomide-PEG1-C2-N3 can be used to design a selective CDK6 PROTAC degrader CP-10. CP-10 induces the degradation of CDK6 with an DC50 of 2.1 nM . Pomalidomide-PEG1-C2-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: